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NUCB2/nesfatin-1 is an anorexigenic hormone with elevated levels in obese and decreased
levels in anorexia nervosa (AN) patients. Moreover, a role in the regulation of stress and
emotions was suggested by several rodent and preliminary human studies. Since anxiety
and depression are common comorbidities in AN, we investigated the association of
NUCB2/nesfatin-1 with anxiety, depression and perceived stress in AN.
Methods
We analyzed circulating NUCB2/nesfatin-1 levels in 64 female inpatients diagnosed with
anorexia nervosa (body mass index, BMI; mean±SD, 14.7±2.3 kg/m2). At the same time
anxiety (GAD-7), depression (PHQ-9), stress (PSQ-20) and disordered eating (EDI-2) were
measured psychometrically.
Results
No correlation was observed between NUCB2/nesfatin-1 and BMI (r = 0.06, p = 0.70). The
study population was divided in patients with low anxiety (n = 32, GAD-7 scores, mean±SD,
7.5±3.3) and high anxiety (n = 32, 16.0±3.0, p<0.001). Patients with high anxiety scores
displayed 65% higher NUCB2/nesfatin-1 levels (p = 0.04). This was reflected by a positive
correlation of GAD-7 and NUCB2/nesfatin-1-levels (r = 0.32, p = 0.04). Scores of PSQ-20
(73.3±14.3 vs. 48.6±17.2) and PHQ-9 (18.8±5.0 vs. 10.3±5.1) were higher in the high anxi-
ety group (p<0.001) but did not correlate with NUCB2/nesfatin-1 (p>0.05). EDI-2 total score
was also higher in the high anxiety group (52.3±14.1 vs. 40.2±16.0, p = 0.02), while no cor-
relations of EDI-2-scores with plasma NUCB2/nesfatin-1 were observed (p>0.05).
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Conclusions
Circulating NUCB2/nesfatin-1 levels correlated positively with perceived anxiety, whereas
no association with BMI or eating disorder symptoms was observed. NUCB2/nesfatin-1
might be primarily involved in the modulation of anxiety and subsequently in the regulation
of eating habits and body weight in AN.
Introduction
Nesfatin-1 is an 82-amino-acid peptide hormone cleaved from nucleobindin2 (NUCB2). First
described in 2006 [1], nesfatin-1 has been considered to be primarily involved in the regulation
of hunger and satiety as an anorexigenic modulator since intracerebroventricular and also
peripheral injection were shown to reduce food intake in rodents [1, 2]. NUCB2/nesfatin-1 is
expressed in several cerebral regions of the rat such as hypothalamus and brainstem [1], amyg-
dala [3–5], and parasympathetic and sympathetic neurons [5]. In humans, it was also detected
in the Edinger-Westphal nucleus [6]. In addition, NUCB2/nesfatin-1 has been shown to occur
also peripherally in human and murine adipose tissue [7]. It is colocalized with insulin in
rodent [8] and human pancreatic beta-cells [9] and colocalized with ghrelin in gastric human
P/D1- and rat X/A-like cells [10, 11]. Interestingly, the stomach seems to be the major source of
NUCB2/nesfatin-1 as expression levels are higher compared to the brain as shown in rats [10].
Since most studies did not distinguish between full length NUCB2 and processed nesfatin-1
due to the fact that the antibodies used also recognize full length NUCB2 (for discussion see
[12]) the analyte should be referred to as NUCB2/nesfatin-1.
The regulation of circulating NUCB2/nesfatin-1 seems to depend on food ingestion with
decreased levels after fasting and a restoration after re-feeding in rats [10], while confirmation
of these data in humans is pending. In addition to the short term alterations, also sustained
changes in body weight have been reported to affect NUCB2/nesfatin-1. The only study con-
ducted in subjects with anorexia nervosa reported lower NUCB2/nesfatin-1 levels compared to
healthy controls [13]. In line with these data several studies showed a positive correlation of
NUCB2/nesfatin-1 levels with body mass index (BMI) [7, 14]. However, this association is not
yet fully established as other studies reported an inverse relationship [15–18] or no significant
association of NUCB2/nesfatin-1 levels and BMI [19]. Alternatively, other factors might more
strongly influence NUCB2/nesfatin-1 levels and thereby alter the expected relationship
between NUCB2/nesfatin-1 and BMI [19].
Recently, NUCB2/nesfatin-1 has been suggested to be also a part of circuitries involved in
the modification of behavioral and emotional responses to stress [20]. In rodents, intracerebro-
ventricular injection of nesfatin-1 – besides reducing food intake – induced anxiety-related
behaviors [21]. Subsequently, several groups showed an activation of NUCB2/nesfatin-1 neu-
rons in rats undergoing restraint stress, a well-established rodent model of psychological stress
[22–24]. In humans, elevated NUCB2 mRNA expression was observed in the brain Edinger-
Westphal nucleus [6] and higher NUCB2/nesfatin-1 peptide levels in the peripheral circulation
[25] of depressed patients compared to healthy controls. In line with these findings, a positive
correlation of anxiety, depression and perceived stress with circulating NUCB2/nesfatin-1 lev-
els has been reported in obese women [19]. Interestingly, male patients with general anxiety
disorders displayed decreased nesfatin-1 levels [26] pointing towards a possible sex-specific
regulation of NUCB2/nesfatin-1.
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The involvement of NUCB2/nesfatin-1 in the regulation of food intake and emotion should
be viewed in an integrated manner since mood and eating habits seem to be interrelated. More-
over, a hormone with anorexigenic and anxiogenic effects might play a role in the etiology or
maintenance of anorexia nervosa which is often accompanied by depression and anxiety [27–
30]. In the present study, we therefore investigated the relationship between NUCB2/nesfatin-
1 and different psychological parameters and hypothesized a positive correlation of NUCB2/
nesfatin-1 primarily with anxiety which has been shown by our group in obese women before
[19]. We also expected positive associations of NUCB2/nesfatin-1 with depression and per-
ceived stress as also shown for obese women in the same study [19]. In addition, we tested
whether patients with high anxiety also display higher scores of depression and perceived stress
and exploratively investigated whether any associations with symptoms of disordered eating
could be observed. Lastly, in a small sample we compared circulating NUCB2/nesfatin-1 levels




All investigations were conducted according to the Declaration of Helsinki and all patients
gave written informed consent. The study was approved by the institutional ethics committee
of the Charité – Universitätsmedizin Berlin (protocol number: EA1/114/10).
Subjects
We enrolled 64 female inpatients suffering from anorexia nervosa (BMI 14.7 ± 2.3 kg/m2;
range 8.7–19.3 kg/m2) and 10 normal weight female inpatients (BMI 20.5 ± 1.6 kg/m2; range
18.6–23.4 kg/m2) at admission to their treatment (consisting of biomedical therapy and physio-
therapy as well as both individual and group psychotherapy, music and art therapy and body
psychotherapy) in the Division of General Internal and Psychosomatic Medicine at Charité –
Universitätsmedizin Berlin. Inclusion criteria for anorexia nervosa patients encompassed
female sex and the fulfillment of ICD-10 (International Statistical Classification of Diseases
and Related Health Problems of the World Health Organization, 10th revision) diagnostic crite-
ria for anorexia nervosa (typical and atypical anorexia nervosa as well as restricting and binge-
purge subtypes) [31]. The atypical subtype was defined as meeting all but one criterion of the
typical form (BMI below 17.5 kg/m2, self-induced weight loss, body image distortion, and
amenorrhea) [31]. ICD-10 criteria for anorexia nervosa basically equal DSM-IV (Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition) criteria [32], while in contrast to
the DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) criteria [33]
amenorrhea is still a criterion for typical anorexia nervosa. Inclusion criteria for normal weight
patients comprised a BMI of 18.5 to 25.0 kg/m2, female sex and the absence of relevant biomed-
ical diagnoses. These patients were admitted to the hospital for the treatment of somatoform,
anxiety, depressive or adjustment disorders. Patients with somatoform disorders of the gastro-
intestinal system were excluded. Exclusion criteria for the whole study were current pregnancy,
psychotic disorders and an age below 18 years.
Anthropometric measurements
Body weight and height were assessed at the same day of blood withdrawal between 07:00–
08:00 am in light underwear and BMI was calculated as kg/m2.
Nesfatin-1 and Anxiety in Anorexia Nervosa
PLOS ONE | DOI:10.1371/journal.pone.0132058 July 10, 2015 3 / 15
Laboratory analyses
Venous blood samples were taken after an overnight fast between 7:00 and 8:00 in the morning.
Patients were allowed to drink small amounts of water but were advised not to drink larger
amounts or other beverages, to eat, smoke or exercise before blood withdrawal. All blood sam-
ples were collected within 3 days after admission to avoid biases due to the onset of metabolic
changes following treatment initiation. The blood was collected in pre-cooled standard EDTA
tubes prepared with aprotinin (1.2 Trypsin Inhibitory Unit per 1 ml blood; ICN Pharmaceuti-
cals, Costa Mesa, CA, USA) for peptidase inhibition. Immediately after blood withdrawal the
tubes were stored on ice and then centrifuged at 4°C for 10 min at 3000 g. Plasma was then sepa-
rated and stored at -80°C until further processing. NUCB2/nesfatin-1 plasma levels were mea-
sured using a commercial enzyme-linked immunosorbent assay (ELISA, catalog # EK-003-26,
Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA). All samples were processed at once
(intra-assay variability was 5%, inter-assay variability was 7%). The antibody used in this ELISA
was raised against nesfatin-1 and also recognizes full length NUCB2 containing the epitope.
Psychometric questionnaires
For psychometrical examination and ad hoc questions about socioeconomic status patients
were given personal digital assistants (PDA) one or two days before or on the day of blood
withdrawal and asked to fill in the following questionnaires within one day.
For assessment of anxiety and depression two scales of the self-report measure patient
health questionnaire (PHQ) [34] were used. For the diagnosis of a generalized anxiety disorder
specificity was 0.92 and sensitivity 0.89 [35]. According to the English version, the German ver-
sion of the GAD-7 [36] utilizes 7 items designed to diagnose general anxiety disorder [35] but
also captures panic, social anxiety or posttraumatic stress symptoms. Cronbach’s alpha for the
present sample was 0.83.
The PHQ-9 depression scale [34], consisting of 9 items, is a widely used screening instrument
for determination of the severity of depressive symptoms. We administered the German version
by Löwe et al. [37]. For the current population Cronbach’s alpha was calculated as 0.86. In a meta-
analysis of 17 validation studies in different languages including the German language translation,
specificity was 0.92 and sensitivity 0.80 for the diagnosis of a major depressive disorder [38].
For the measurement of stress we used the perceived stress questionnaire (PSQ) [39] in its
revised German version with 20 items (PSQ-20) [40]. The PSQ emphasizes the subjective per-
ception of stress and additionally provides four subscales evaluating “worries”, “tension”, and
“joy” as stress responses and “demands” as a perception of external stressors. Cronbach’s alpha
for the subscales ranged from 0.83 to 0.87.
The Eating Disorder Inventory (EDI) was developed [41] to assess eating disorder symp-
toms in anorexic and bulimic patients and is also a self-report instrument encompassing 64
items on 8 subscales measuring “drive for thinness”, “bulimia”, “body dissatisfaction”, “ineffec-
tiveness”, “perfectionism”, “interpersonal distrust”, “interoceptive awareness”, and “maturity
fears”. We used the German version [42] of the 2nd version [43] which added 3 subscales to the
original one but only used the above mentioned first 8 subscales of the EDI-2. Cronbach’s
alpha was determined as 0.87.
Statistical analysis
Distribution of the data was determined by Kolmogorov-Smirnov test. For descriptive charac-
terization of demographic and anthropometric data, t-tests and Mann-Whitney-U-tests were
employed depending on the distribution of the data. For descriptive characterization of socio-
economic data and anorexia nervosa subtypes frequencies were calculated using crosstabs
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followed by χ2-tests. Correlations were determined by Pearson’s or Spearman’s analyses
depending on the distribution of the data. Differences in outcome variables between groups
were calculated using t-tests. Differences between groups were considered significant when
p< 0.05. Data are expressed as mean ± standard deviation (SD) for parametric data and as
median (25th percentile/75th percentile) for non-parametric data. Statistical analyses were con-
ducted using SigmaStat 3.1 (Systat Software, San Jose, CA, USA).
Results
According to the results in the GAD-7 we divided our sample into two groups, one with low
and one with high anxiety levels by splitting the sample at the median score of 12.
Demographic and socioeconomic characteristics, duration of disease and subtypes of the
anorexia nervosa study population (n = 64) are described in Table 1. Comorbidities and addi-
tional laboratory analyses in anorexia nervosa patients are shown in S1 Table.
Circulating NUCB2/nesfatin-1 levels show a positive correlation with
anxiety while they are not associated with depression and perceived
stress in anorexic patients
The two study groups (low anxiety: n = 32, GAD-7 score range: 0 to 12, mean ± SD: 7.5 ± 3.3;
high anxiety: n = 32, GAD-7 score range: 12 to 21, mean ± SD: 16.0 ± 3.0, p< 0.001) did not
differ in age (p = 0.33; Table 1), or BMI (p = 0.79; Table 1).
The high anxiety group displayed 65% higher NUCB2/nesfatin-1 levels than the low anxiety
group (0.28 ± 0.25 vs. 0.17 ± 0.07 ng/ml, p = 0.04; Fig 1A) which was reflected by a positive
Table 1. Demographic and socioeconomic characteristics, duration of disease and subtypes of anorexia nervosa of the anorexia nervosa study
population.
Parameter Low anxiety (n = 32) High anxiety (n = 32) Missing data p
Demographic characteristics
Age (years) 23.0 (19.0/30.5) 25.0 (21.3/31.3) 0 0.33a
Body mass index (kg/m2) 14.8 ± 2.0 14.6 ± 2.6 0 0.73b
Duration of disease 6.0 (1.0/14.0) 6.0 (1.1/11.2) 1 0.94a
Socioeconomic characteristics
Living in a partnership (yes/no) 11/17 9/20 7 0.51c
Level of education 7 0.88c
university entrance diploma 7 11
vocational diploma 2 2
level 1 certiﬁcate 14 12
certiﬁcate of secondary education 4 3
without 1 1
Current employment (yes/no) 7/21 7/22 7 0.94c
Unemployment during past 5 years (yes/no) 10/18 10/19 7 0.92c
Anorexia nervosa subtype 0 0.37c
restricting type 11 16
purging type 10 6
atypical anorexia nervosa 11 10
Statistical analyses: Normal distribution was determined by Kolmogorov-Smirnov test. Differences between groups:
a Mann-Whitney-U-test, data expressed as median (25th percentile/75th percentile)
b t-test, data expressed as mean ± standard deviation
c χ2-tests.
doi:10.1371/journal.pone.0132058.t001
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correlation of NUCB2/nesfatin-1 with GAD-7-scores in the whole study sample when treated
as a continuous variable (r = 0.32, p = 0.04; Fig 1B). No correlations were observed for NUCB2/
nesfatin-1 with age (r = 0.02, p = 0.89) or BMI (r = 0.06, p = 0.70; Table 2).
As expected, the high anxiety group also showed a higher depression score (PHQ-9, +83%,
p< 0.001; Fig 2A), perceived stress total score (PSQ-20, +51%, p< 0.001; Fig 2B) and higher
scores on the PSQ-20 subscales “worries” (+66%, p< 0.001; Fig 2C), “tension” (+42%,
p< 0.001; Fig 2D), and “demands” (+74%, p< 0.001; Fig 2E) and lower scores on the “joy”
subscale (-47%, p< 0.001; Fig 2F) compared to the low anxiety group. However, no correla-
tions were detected between NUCB2/nesfatin-1 and depression (PHQ-9 score; r = -0.12,
p = 0.52; Fig 1C), perceived stress (PSQ-20 total score; r = 0.05, p = 0.75; Fig 1D) as well as all
PSQ-20-subscales (Table 2).
Fig 1. GAD-7, PHQ-9, PSQ-20 and EDI-2 scores and plasma NUCB2/nesfatin-1 levels in anorexic
patients. Patients with high anxiety displayed significantly higher NUCB2/nesfatin-1 levels compared to those
with low anxiety (A). This resulted in a positive correlation of NUCB2/nesfatin-1 with anxiety in the whole
anorexic patient sample (B), whereas depression scores (C), perceived stress scores (D) and eating disorder
symptoms (E) did not correlate with plasma NUCB2/nesfatin-1. Differences between groups were calculated
using t-tests. Data are expressed as mean ± standard deviation. * p < 0.05. Distribution of the data was
determined by Kolmogorov-Smirnov test. Correlations were determined by Pearson’s or Spearman’s analyses
depending on the distribution of the data. Values for r and p are indicated in the graph. Abbreviations: EDI-2,
eating disorder inventory; GAD-7, general anxiety disorder questionnaire; NUCB2, nucleobindin2; PHQ-9,
patient health questionnaire depression; PSQ-20, perceived stress questionnaire.
doi:10.1371/journal.pone.0132058.g001
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Circulating NUCB2/nesfatin-1 levels are not associated with eating
disorder symptoms in anorexic patients
Patients with high anxiety levels exhibited higher scores on the EDI-2 total score compared to
the low anxiety group (+30%, p = 0.01; Fig 3A). This resulted from their higher scores on the
EDI-2 subscales “perfectionism” (+40%, p = 0.009; Fig 3E), “ineffectiveness” (+36%, p = 0.03;
Fig 3G) and “interoceptive awareness” (+68%, p< 0.001; Fig 3H), while no significant
differences were observed for the subscales “drive for thinness” (p = 0.18; Fig 3B), “bulimia”
(p = 0.70; Fig 3C), “body dissatisfaction” (p = 0.12; Fig 3D), “interpersonal distrust” (p = 0.09;
Fig 3F), and “maturity fears” (p = 0.96; Fig 3I). However, no correlations were detected between
circulating NUCB2/nesfatin-1 levels and the EDI-2 total score (r = -0.14, p = 0.51; Fig 1E) or all
subscale scores in the population of anorexic patients (Table 2).
Circulating NUCB2/nesfatin-1 levels tend to be higher in normal weight
compared to anorexic patients and to correlate positively with anxiety,
depression, perceived stress and eating disorder symptoms in normal
weight patients
In a small sample we compared circulating NUCB2/nesfatin-1 levels of 10 anorexia nervosa
patients with a sample of 10 normal weight subjects matched for sex, age and anxiety scores.
The socioeconomic characteristics of the anorexia nervosa and the normal weight patient
Table 2. Correlation of NUCB2/nesfatin-1 plasma levels with demographic and psychometric parame-
ters of the anorexia nervosa study population (n = 64).
Parameter r p
Age 0.02 0.89
Body mass index (kg/m2) 0.06 0.70
GAD-7 score 0.32 0.04
PHQ-9 score -0.12 0.52





EDI-2 total score -0.14 0.51
drive for thinness -0.19 0.35
bulimia -0.12 0.55
body dissatisfaction -0.01 0.97
perfectionism -0.22 0.28
interpersonal distrust -0.02 0.94
ineffectiveness -0.18 0.38
interoceptive awareness 0.05 0.80
maturity fears -0.11 0.61
Statistical analysis: Normal distribution was determined by Kolmogorov-Smirnov test. Correlation analysis
was conducted by Pearson’s or Spearman’s analysis, respectively. Signiﬁcant correlations are displayed in
bold. Abbreviations: EDI-2, eating disorder inventory; GAD-7, general anxiety disorder questionnaire;
NUCB2, nucleobindin2; PHQ-9, patient health questionnaire depression; PSQ-20, perceived stress
questionnaire.
doi:10.1371/journal.pone.0132058.t002
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populations are described in S2 Table. The main and secondary diagnoses and the duration of
disease in matched normal weight and anorexia nervosa patients are shown in S3 Table.
Normal weight patients displayed about twofold higher NUCB2/nesfatin-1 levels compared
to matched anorexia nervosa patients (0.393 ± 0.368 vs. 0.156 ± 0.09 ng/ml; Fig A in S1 File).
However, this result only tended to be significant (p = 0.08). In the normal weight patient sub-
group, NUCB2/nesfatin-1 also showed the tendency towards a correlation with GAD-7 scores,
but also missed significance (r = 0.64; p = 0.06; Fig B in S1 File). Strong positive correlations
were observed for NUCB2/nesfatin-1 and PHQ-9 (r = 0.70; p = 0.03; Fig C in S1 File), PSQ-20
(r = 0.78; p< 0.01; Fig D in S1 File), and EDI-2 (r = 0.79; p = 0.03; Fig E in S1 File) scores.
Fig 2. PHQ-9 and PSQ-20 scores of anorexic patients with low versus high anxiety. Patients with high
anxiety scores displayed higher total scores in PHQ-9 (A) and PSQ-20 (B). Similarly, the PSQ-20 subscales
differed between the two groups with higher scores for “worries” (C), “tension” (D) and “demands” (E) and
lower scores for “joy” (F) in the high versus low anxiety group. Differences between groups were calculated
using t-tests. Data are expressed as mean ± standard deviation. *** p < 0.001. Abbreviations: PHQ-9,
patient health questionnaire; PSQ-20, perceived stress questionnaire.
doi:10.1371/journal.pone.0132058.g002
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Discussion
Nesfatin-1 has been implicated in the regulation of satiety and body weight [44]. Early on, the
involvement of NUCB2/nesfatin-1 was also shown in the stress response of rodents and more
recently also an implication of NUCB2/nesfatin-1 in the regulation of anxiety and depression
in humans was described [20]. In the present study we evaluated the association between circu-
lating NUCB2/nesfatin-1 and anxiety in anorexia nervosa. As hypothesized, we observed sig-
nificantly higher NUCB2/nesfatin-1 plasma levels in female anorexic patients displaying high
anxiety scores compared with those exhibiting low anxiety scores which resulted in a positive
correlation of NUCB2/nesfatin-1 with anxiety scores. However, no correlations were detected
for NUCB2/nesfatin-1 with perceived stress, depression and eating disorder-related behaviors,
attitudes and cognitions.
The result of a positive association of NUCB2/nesfatin-1 with anxiety is in line with our pre-
vious finding in female obese patients showing higher levels of NUCB2/nesfatin-1 in subjects
Fig 3. EDI-2 scores of anorexic patients with low versus high anxiety.Patients with high anxiety scores
displayed a higher EDI-2 total score (A) and higher values of the subscales “perfectionism” (E), “ineffectiveness”
(G) and “interoceptive awareness” (H) compared to those with low anxiety, while the subscales “drive for
thinness” (B), “bulimia” (C), “body dissatisfaction” (D), “interpersonal distrust” (F) and “maturity fears” (I) did not
differ between the two groups. Differences between groups were calculated using t-tests. Data are expressed
asmean ± standard deviation. * p < 0.05, ** p < 0.01 and *** p < 0.001. Abbreviations: EDI-2, eating disorder
inventory.
doi:10.1371/journal.pone.0132058.g003
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with increased anxiety which was also reflected in a strong correlation of NUCB2/nesfatin-1
with anxiety scores [19]. In addition, these data corroborate preclinical findings of a link
between nesfatin-1 and anxiety as well as stress-induced anxiety-like behavior in rodents [21–
24]. Interestingly, one recent human study detected decreased NUCB2/nesfatin-1 plasma levels
in male patients with the diagnosis of a generalized anxiety disorder compared to healthy con-
trols [26] which could point towards a sex-specific regulation of NUCB2/nesfatin-1. This con-
cept was also proposed in a study investigating brain NUCB2 expression in depressed suicide
victims compared to controls who did not die as a consequence of neuropsychiatric disorders.
While male subjects had higher midbrain NUCB2 mRNA levels compared to controls, in
females an inverse relationship was described [6]. This would suggest an inverse expression of
central and peripheral NUCB2/nesfatin-1 in males and females under conditions of anxiety
and depression which warrants further research to investigate this possible sex-specific effect.
In light of the proximity of the psychological constructs of depression and anxiety we also
expected a positive association of NUCB2/nesfatin-1 and depression in the present study popu-
lation. One study reported a positive correlation of plasma NUCB2/nesfatin-1 with depression
(measured by Hamilton Depression Rating Scale, HAM-D) in a mixed-sex population of
patients diagnosed with major depressive disorder and a healthy control group [25]. In addi-
tion, we recently described a positive association of NUCB2/nesfatin-1 with depression (mea-
sured by PHQ-9) in obese women [19]. However, in the present population of female subjects
with anorexia nervosa we did not observe a correlation of NUCB2/nesfatin-1 with depression
as indicated by PHQ-9. Moreover, an association of circulating NUCB2/nesfatin-1 with per-
ceived stress, a finding reported before in obese women [19], was also absent in the current
study population. Besides the fact that the above mentioned sex-specific effects might have
contributed to these differential results, the psychometric mean of assessment of depression
could also influence the observed outcome. Although HAM-D and PHQ-9 both measure and
quantify depression, they may determine different aspects since the HAM-D is an external
while the PHQ-9 is a self-assessment questionnaire [45, 46]. However, most likely these differ-
ential results in obese versus anorexic patients are due to a stronger association of NUCB2/
nesfatin-1 with anxiety than depression or perceived stress that emerges when NUCB2/nesfa-
tin-1 plasma levels are overall low as observed in the present anorexic population (0.22 ± 0.19
ng/ml) compared to obese women (0.40 ± 0.13 ng/ml) [19].
Nesfatin-1 is a well-established anorexigenic hormone in rodents and NUCB2/nesfatin-1
blood levels were reported to be reduced in patients with restricting-type anorexia nervosa [13]
suggesting an implication of this peptide in the onset, course or maintenance of the disease.
However, no further studies in anorexic subjects were conducted to date. Moreover, until now
studies are lacking that investigate the relationship between NUCB2/nesfatin-1 and behaviors,
cognitions or attitudes in eating disorders. In the present study, we did not detect an associa-
tion of circulating NUCB2/nesfatin-1 with the total score of EDI-2 or its subscales in subjects
with anorexia nervosa. Thus, NUCB2/nesfatin-1 does not seem to be involved in the specifi-
cally pathological eating behavior displayed by anorexic patients. However, in light of the cor-
relation of NUCB2/nesfatin-1 with anxiety one might hypothesize that NUCB2/nesfatin-1 is
primarily involved in the mediation of anxiety symptoms and subsequently influences food
intake, potentially contributing to worse outcomes in a very anxious subgroup of anorexia ner-
vosa patients.
Early on, a positive association of circulating NUCB2/nesfatin-1 and BMI has been reported
in normal weight to obese [7] and normal weight study populations [14]. In line with these
data, anorexic subjects were reported in one study to have lower NUCB2/nesfatin-1 levels com-
pared to healthy controls [13]. However, in the present study we did not observe an association
of NUCB2/nesfatin-1 with BMI in anorexic patients. This is most likely due to the low BMI
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spectrum investigated ranging from 9 to 19 kg/m2 and overall very low NUCB2/nesfatin-1
plasma levels. Interestingly, also recent studies challenged the initially described positive asso-
ciation of NUCB2/nesfatin-1 and BMI by reporting a negative correlation in normal weight to
low grade obese subjects [15–18], or a lacking correlation in a very obese population [19]. In
light of the emerging evidence on the association between NUCB2/nesfatin-1 and anxiety these
inconsistent findings might be likely due to confounding factors such as anxiety which have
not been assessed in these studies.
In the small sample of normal weight patients NUBC2/nesfatin-1 showed a tendency
towards a correlation with anxiety scores, however, without reaching statistical significance.
These significances were reached with positive correlations between NUCB2/nesfatin-1 and
depression, perceived stress and eating disorder symptoms giving rise to a regulation of
NUCB2/nesfatin-1 in a similar manner compared to anorexia nervosa. Normal weight patients
also displayed a tendency towards a significant difference with markedly higher NUCB2/nesfa-
tin-1 levels compared to anorexic patients which may be due to the influence of the higher
body weight compared to anorexia nervosa. The narrowly missed significances may be due to
the small group size. Future studies with larger sample sizes are warranted to investigate possi-
ble differences in the regulation of NUCB2/nesfatin-1 with regards to anxiety, depression, per-
ceived stress, and eating disorder symptoms in normal weight patients.
Several limitations have to be considered when interpreting these data. First, we did not
investigate NUCB2/nesfatin-1 in its association with nosological diagnoses as generalized
anxiety disorder or major depressive disorder and did not provide a standardized diagnostic
assessment. However, one has to take into account that most likely it is not the diagnostic
classification but rather the individually perceived burden of symptoms as anxiousness, depres-
siveness, perceived stress or eating disorder symptoms such as “body dissatisfaction” or “inef-
fectiveness that might be associated with altered hormone levels. In this context, constructs like
anxiousness or depressiveness most likely are better operationalized as continuous rather than
categorial variables. Nevertheless, as mentioned above the psychometric instruments used in
this study are self-assessment questionnaires which might be affected by inaccurate self-report-
ing caused by recall bias, social desirability or difficulties in self-observation. However, these
questionnaires are well validated and suitable for bedside application for the measurement of
perceived burden of symptoms in naturalistic study designs. Second, we did not employ a
healthy control group. However, it was not our main aim to compare NUCB2/nesfatin-1 levels
of healthy controls with anorexic subjects but to investigate whether NUCB2/nesfatin-1 shows
a positive correlation with anxiety also in female anorexic subjects. Third, due to the rather
small sample sizes we potentially were not able to detect associations between peripheral
NUCB2/nesfatin-1 levels and scores of PHQ-9, PSQ-20 and EDI-2. This warrants further
examination in future studies. Finally, circulating NUCB2/nesfatin-1 levels might be affected
by circadian variations and all variables studied in the present investigation are known to be
affected by several other influencing factors. However, considering all relevant confounding
variables would require larger study populations and a measurement of a broad variety of
items which is beyond the scope of the current first study. This should be addressed in future
studies using multiple regression analysis models.
Conclusions
As the main finding supporting the initial hypothesis we observed a significant correlation of
NUCB2/nesfatin-1 with anxiety in a population of anorexic patients. Unexpectedly, no associa-
tion was found for NUCB2/nesfatin-1 with depression and perceived stress, giving rise to a pre-
dominant link of NUCB2/nesfatin-1 with anxiety and anxiety-like behaviors. Longitudinal and
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interventional studies in different populations are needed in order to further investigate
NUCB2/nesfatin-1’s implication in the regulation of anxiety and the causal direction of this
interrelation. In addition, we exploratively did not observe an association of NUCB2/nesfatin-1
with eating disorder symptoms as measured by the EDI-2 making NUCB2/nesfatin-1 unlikely
to be directly involved in eating disorder pathology in anorexia nervosa.
In synopsis with the existing literature we therefore hypothesize that NUCB2/nesfatin-1
might be primarily involved in the mediation of anxiety and that its well-described influence
on food intake and body weight is independent from disordered eating – at least in patients
with anorexia nervosa. However, due to the anorexigenic properties of NUCB2/nesfatin-1
more anxious anorexic patients might be at greater risk for unfavorable outcomes than those
with lower tendency to anxiousness.
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